Opicapone in Parkinson’s Disease

In its first-quarter earnings conference call, Neurocrine Biosciences (NBIX) highlighted plans to submit an NDA (new drug application) seeking approval for an investigational catechol-O-methyltransferase inhibitor, Opicapone, for treating multi-fluctuation in PD (Parkinson’s disease) patients, in the second quarter. In 2016, the drug was launched in the European market by BIAL under the trade name of ONGENTYS. In February 2017, Neurocrine Biosciences entered an in-licensing agreement with BIAL for Opicapone.

According to Neurocrine Biosciences’ first-quarter earnings investor presentation, around 1 million people are affected by PD in the US. Two out of every three PD patients are on carbidopa/levodopa therapy, considered as a standard of care regimen. However, since these regimens have been shown to lose their efficacy over time, dosage and frequency of dosage need to be adjusted multiple times, which highlights the significant unmet demand in this segment.

Neurocrine Biosciences Has Robust Late-Stage PipelineElagolix in uterine fibroids

Neurocrine Biosciences expects partner AbbVie (ABBV) to submit an NDA seeking FDA approval for Elagolix in the uterine fibroids indication in mid-2019. According to Neurocrine Biosciences’ first-quarter earnings investor presentation, Elagolix was discovered and developed up to Phase 2 by Neurocrine Biosciences and was then developed by AbbVie. Around three million women in the US are diagnosed with symptomatic uterine fibroids, while 450,000 new patients are diagnosed annually. Additionally, 250,000 hysterectomies are performed annually to manage the symptoms associated with uterine fibroids. Since only one drug has been approved by the FDA in the past 20 years for this indication, Elagolix is expected to target a largely underserved market opportunity.

NBI-74788 in CAH

According to Neurocrine Biosciences’ first-quarter earnings investor presentation, the company plans to begin a Phase 2 trial evaluating investigational therapy NBI-74788 in theCAH (congenital adrenal hyperplasia) indication in the third quarter. In March 2019, the company issued a press release announcing positive interim results from the Phase II proof-of-concept study evaluating NBI-74788 in the CAH indication.

According to Neurocrine Biosciences’ first-quarter earnings investor presentation, the company expects to have a portfolio of three assets approved across four indications by the end of fiscal 2020.

Latest articles

WeWork is gearing up for an IPO. On Wednesday, the company made its IPO filing with the SEC public and expects to garner $3.5 billion from its IPO.

After FCC Chairman Ajit Pai recommended the approval of the T-Mobile–Sprint merger, Representative David Cicilline urged the FCC to allow public comment.

Cresco Labs (CRLBF) is set to report its Q2 earnings on August 21 after the market closes. The company's stock fell 5.3% yesterday.

Cannabis stocks mostly traded in positive territory today. Supreme Cannabis (FIRE) and Aurora Cannabis (ACB) rose about 9.5% and 5.5%, respectively.

NVIDIA (NVDA) stock soared 6% in today’s trading session as its Q2 earnings for fiscal 2020 beat estimates. However, its guidance missed estimates.

Nio Inc. (NIO) has disrupted the automotive space since 2014 but only made waves in the market since its IPO. Investors have suffered numerous setbacks.